Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study 1 1 Herbert Schuster is the principal investigator of the MERCURY I trial, which is sponsored by AstraZeneca; he also serves on the International Rosuvastatin Advisory Board. Philip J. Barter is an investigator of the MERCURY I trial and also serves on the International Rosuvastatin Advisory Board. Steen Stender, Raphael C. Cheung, Jacques Bonnet, and Jonathan M. Morrell are investigators of the MERCURY I trial. Claire Watkins, David Kallend, and Ali Raza are employees of AstraZeneca.
Titel:
Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study 1 1 Herbert Schuster is the principal investigator of the MERCURY I trial, which is sponsored by AstraZeneca; he also serves on the International Rosuvastatin Advisory Board. Philip J. Barter is an investigator of the MERCURY I trial and also serves on the International Rosuvastatin Advisory Board. Steen Stender, Raphael C. Cheung, Jacques Bonnet, and Jonathan M. Morrell are investigators of the MERCURY I trial. Claire Watkins, David Kallend, and Ali Raza are employees of AstraZeneca.
Auteur:
Schuster, Herbert Barter, Philip J Stender, Steen Cheung, Raphael C Bonnet, Jacques Morrell, Jonathan M Watkins, Claire Kallend, David Raza, Ali